Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibiting 15-PGDH restores redox homeostasis and confers neuroprotection in Parkinson's disease.

Redox biology·2026
Same author

Bioprocess Development of a Human Monoclonal Antibody against MERS-CoV: Analytical and Preclinical Studies.

Biomolecules & therapeutics·2026
Same author

Thiazole-Linked <i>N</i>-Hydroxypropanamide Derivatives: Selective HDAC6 Inhibitors with Therapeutic Potential for Neurodegenerative Diseases.

Journal of medicinal chemistry·2026
Same author

Corrigendum to "Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid β-peptide and the membrane lipid peroxidation product 4-hydroxynonenal" [Experimental Neurology, vol. 213,1 (2008): 114-21].

Experimental neurology·2026
Same author

Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides.

Signal transduction and targeted therapy·2026
Same author

Peripheral biomarkers of neuroinflammation in Alzheimer's disease and vascular dementia.

Biochemical pharmacology·2026
Same journal

Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens.

Biomaterials research·2026
Same journal

Targeted Sirtuin 3 Activation by Biomimetic Black Phosphorus Nanosheets Mitigates Sepsis-Induced Acute Kidney Injury through Yeast Mitochondrial Escape 1-Like 1 Deacetylation.

Biomaterials research·2026
Same journal

A Hybrid Mesenchymal-Stem-Cell-Derived Decellularized Matrix Scaffold Supports Bone Repair and Vascular Perfusion in Steroid-Associated Osteonecrosis.

Biomaterials research·2026
Same journal

Biomimetic Nanogels Programmed for Irreversible-Electroporation-Primed Tumor Microenvironments to Elicit Durable Antitumor Immunity.

Biomaterials research·2026
Same journal

Restoring Zinc Homeostasis via a Bimetallic Nanozyme to Amplify Ferroptosis and Antitumor Immunity for Prostate Cancer Treatment.

Biomaterials research·2026
Same journal

Bioactive Chitin-Based Thermosensitive Hydrogel Reinforces Stem Cell Therapy for Osteoarthritis.

Biomaterials research·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2025

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
08:43

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery

Published on: February 14, 2017

10.9K

PEDF-Enriched Extracellular Vesicle for Vessel Normalization to Potentiate Immune Checkpoint Blockade Therapy.

Sol Shin1,2, Chan Ho Kim2, Soyoung Son1,2

  • 1Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06355, Republic of Korea.

Biomaterials Research
|October 2, 2024
PubMed
Summary
This summary is machine-generated.

Engineered extracellular vesicles carrying antiangiogenic pigment epithelium-derived factor (PEDF) normalize tumor vasculature. This approach enhances immune checkpoint inhibitor (ICI) therapy, improving T cell infiltration and antitumor immunity in refractory tumors.

More Related Videos

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

653
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

Related Experiment Videos

Last Updated: Jun 11, 2025

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
08:43

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery

Published on: February 14, 2017

10.9K
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

653
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

Area of Science:

  • Biomedical Engineering
  • Cancer Immunology
  • Nanomedicine

Background:

  • Abnormal tumor vasculature impedes T cell infiltration, reducing the effectiveness of immune checkpoint inhibitors (ICIs).
  • Targeting tumor vasculature is a strategy to overcome resistance to ICIs.

Purpose of the Study:

  • To develop antiangiogenic extracellular vesicles (EVs) for tumor vasculature normalization.
  • To enhance the efficacy of ICIs by delivering pigment epithelium-derived factor (PEDF) via EVs.

Main Methods:

  • Small EVs were engineered to encapsulate PEDF, creating PEDF-enriched EVs (P-EVs).
  • In vitro assays assessed P-EVs' effects on endothelial cells.
  • In vivo studies in tumor-bearing mice evaluated P-EVs' impact on tumor vasculature and immune response, alone and with anti-PD-1 antibodies.

Main Results:

  • P-EVs demonstrated antiangiogenic properties in vitro.
  • In vivo, P-EVs reduced vessel leakiness, improved blood perfusion, and decreased tumor hypoxia.
  • Combination therapy with P-EVs and anti-PD-1 antibodies significantly increased CD8+ T cell infiltration and reduced regulatory T cells, enhancing antitumor immunity.

Conclusions:

  • PEDF-enriched EVs effectively normalize tumor vasculature and potentiate anti-PD-1 therapy.
  • P-EVs represent a promising therapeutic strategy for tumors resistant to ICIs.